Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer. - Wikidata - awgldk - TriplyDB

Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.

Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.

http://www.wikidata.org/entity/Q34749852

about

KRAS Mutation Detection in Non-small Cell Lung Cancer Using a Peptide Nucleic Acid-Mediated Polymerase Chain Reaction Clamping Method and Comparative Validation with Next-Generation Sequencing.KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer.Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in Taiwan Pleural involvement in lung cancer.KRAS mutant lung cancer: progress thus far on an elusive therapeutic target.Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.Targeting Nonsquamous Nonsmall Cell Lung Cancer via the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]Pyrimidine Thienoyl Antifolates.Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia.KRAS and the Reality of Personalized Medicine in Non-small Cell Lung Cancer.KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis.Selumetinib for the treatment of non-small cell lung cancer.Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.Altered Transcriptional Control Networks with Trans-Differentiation of Isogenic Mutant-KRas NSCLC Models.Characterization of distinct types of KRAS mutation and its impact on first-line platinum-based chemotherapy in Chinese patients with advanced non-small cell lung cancer.Prognostic significance of EGFR and KRAS mutations in NSCLC patients with brain metastases treated with radiosurgery†.The efficacy of first-line chemotherapy is associated with KRAS mutation status in patients with advanced non-small cell lung cancer: a meta-analysis.Should KRAS mutation still be used as a routine predictor of response to EGFR-TKIs in advanced non-small-cell lung cancer? A revaluation based on meta-analysis.

P2860

Q33634165-9FC6E2CF-4655-469F-AB3A-48899F07F7F4 Q33690682-8CD51B74-4500-4986-8778-BB4EC963E047 Q33754779-9AFBC7BB-4F4E-4474-B26E-3181FC353E09 Q35034044-781A2529-FCA8-4392-93A1-773A392F10B6 Q35196603-6B260A4C-21F2-48B0-9A13-2111320A144F Q35739559-512885CD-41A9-4B8F-8FA9-875A5DA2AE75 Q36369197-BBA40492-DE6E-4894-98E3-FC0C2033AB79 Q36557569-5B4FA7EC-4C34-4B8A-89B4-6525967B8028 Q36733474-D3C46885-C20B-414A-AA69-97C672699EE0 Q36834504-E1D85991-482D-40CC-A2FA-9E0815293B5B Q36946809-5F698260-40F6-4C02-A269-3F058EE2AD35 Q37246286-312188BD-8AFC-484E-B3E3-8880D9152291 Q37272817-7246AC9E-0891-4FD1-A70F-54BEB16C2668 Q37353957-92B2FB71-CED6-46ED-BEDE-670DC79FAA60 Q37554470-301C4B98-9949-448D-8F3F-C8B1DDF99BE5 Q38663069-AC601951-521A-4392-9AB6-EEF94CFA0B41 Q38682370-7F06F23A-4F8A-474C-A93B-63472AB9D854 Q41582923-7EA91BC5-B5E0-4040-85A3-69A327F42D07 Q47147655-4E13EAA3-8790-47A4-9806-7CC5F2534608 Q48394926-7A4085BB-4565-4BA5-9A4C-AB5460F1CC9B Q53165144-4783BF21-F08E-4092-BBD4-9EA0A43A3520 Q53647606-3045810D-DAAF-42DE-94B4-3A98AD286840

P2860

Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.

http://www.wikidata.org/entity/Q34749852

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.

@ast

Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.

@en

Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.

@nl

type

label

Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.

@ast

Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.

@en

Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.

@nl

prefLabel

Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.

@ast

Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.

@en

Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.

@nl

P1433

Q34749852-41C89701-E47C-4A33-8B92-33FFB0494309

P1476

Q34749852-2F7B1B23-29C1-43D9-BD28-6E34A5946C98

P2093

Q34749852-226503F7-53FB-4F92-A389-A1797DED3B15

Q34749852-381616B0-9ECF-4A69-9434-CF327A6C0C30

Q34749852-3EBB20A9-7879-4136-9378-39B4FC9C10F4

Q34749852-4CCA26BA-E033-4B01-8E56-323253426EA4

Q34749852-95B74348-8FDC-44F5-B302-A64C4FB49F8D

P2860

Q34749852-0F876571-C098-4F9C-88B0-B1EB642F24E7

Q34749852-14FE320A-D7B8-4B97-BF30-11521E8CB774

Q34749852-183FB9E9-A997-4913-9886-099AFF09361F

Q34749852-1D6C1774-8E29-4DB8-886F-4BB4EE7E0CAA

Q34749852-21617654-F32F-4A26-89AE-EF6B9594776C

Q34749852-27D2B33A-C54B-4B6A-B4A3-EA0BA430C248

Q34749852-2D400F53-0749-4524-912F-C5E35C94F5ED

Q34749852-4EEE7F15-3B4A-41D4-8510-0BAAD4F2E494

Q34749852-538EC03B-AB44-4553-90E1-E44D9587A921

Q34749852-81F4DFB8-B0D0-4849-96DB-982DFCE57E6A

P304

Q34749852-1466930C-7121-4A2C-AEB8-6ABD44FF21CC

P31

Q34749852-F0E533DF-719A-412F-99F0-29544D9424E2

P356

Q34749852-3DCBB9F3-454F-40B4-8ECC-4199C4BE2B34

P407

Q34749852-00563E09-4996-4FF9-AAC9-F26F288AEAA5

P433

Q34749852-9A520574-E6A0-452B-8FB4-0BC4477FE458

P478

Q34749852-8465729A-44A8-482D-B843-DB838C7F67E1

P577

Q34749852-31993CA5-EDCC-452C-AE98-B3542C5F2EC2

P5875

Q34749852-E2DBEACC-6618-45DE-A1D2-1871133B0F59

P698

Q34749852-AE071B5B-5F52-406A-A3BB-835062C8813C

P932

Q34749852-150A2A4D-1830-464C-8A82-F1883C25448E

P356

JOURNAL.PONE.0064816

P1433

P1476

Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.

@en

P2093

Deok Won Hwang

http://www.w3.org/2001/XMLSchema#string

Jin Seok Ahn

http://www.w3.org/2001/XMLSchema#string

Jong-Mu Sun

http://www.w3.org/2001/XMLSchema#string

Keunchil Park

http://www.w3.org/2001/XMLSchema#string

Myung-Ju Ahn

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.

A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.

Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Benchmarking of mutation diagnostics in clinical lung cancer specimens

P304

e64816

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0064816

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236978651

http://www.w3.org/2001/XMLSchema#string

P698

23724098

http://www.w3.org/2001/XMLSchema#string

P932

3665805

http://www.w3.org/2001/XMLSchema#string